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Abstract
Unresectable massive T4 breast tumor cannot be controlled by radiotherapy of £70Gy. Modiﬁed SIB irradiation
technique enables to irradiate ‡100Gy to the tumor, keeping dose to the surrounding healthy tissue within
tolerance dose. Huge tumors of all 3 patients enrolled in the clinical trial macroscopically disappeared by
modiﬁed SIB radiotherapy.
Background: The purpose of this study was to evaluate the effect of modiﬁed simultaneous integrated boost (SIB)
radiotherapy for patients with extensive breast cancer. Patients and Methods: Patients with macroscopic tumor
and histologically proven adenocarcinoma of the breast were enrolled in the study. Patients were included whether
they had or did not have previous surgery, chemotherapy, hormone therapy, or molecular targeted therapy; patients
with past history of thoracic radiotherapy were excluded. Under conditions of not exceeding the tolerance dose for
normal tissue, irradiation to the tumor was increased to the maximum possible extent using the modiﬁed SIB
technique. Results: Three breast cancer patients were treated with the modiﬁed SIB technique. All patients were
diagnosed as T4b (median maximum diameter of the tumor: 16 cm; range, 15.5-22 cm), and all patients exhibited
symptoms because of the extremely large tumor. The median total dose to the part of tumor tissue was 128.8 Gy
(range, 110-140 Gy). Total dose to normal tissue was < 72 Gy in all patients. Although large tumors were radio-
resistant, it was macroscopically conﬁrmed that all tumors eventually disappeared. Although skin defects per-
sisted because of tumor disappearance, there were no Grade  3 toxicities due to radiotherapy. Conclusion:
Although much care is required in delivering extremely high doses of radiotherapy to the tumor, modiﬁed SIB
radiotherapy was shown to be effective against extremely large tumors that could not be controlled using con-
ventional radiotherapy. In future, an increase in the number of study patients and establishment of the technique will
be required.
Clinical Breast Cancer, Vol. 15, No. 2, 161-7 ª 2015 The Authors. Published by Elsevier Inc. All rights reserved.
Keywords: Breast neoplasm, Clinical trial, Radiotherapy, Technique, Unresectable tumorIntroduction chemotherapy, radiotherapy (RT), and hormone therapy are mainly
The incidence of advanced breast cancer is 80-120 per 1,000,000
people.1,2 For patients with locally advanced breast cancer,*This is an open access article under the CC BY-NC-SA license (http://
creativecommons.org/licenses/by-nc-sa/3.0/).
1Department of Radiation Oncology, National Institute of Radiological Sciences,
Chiba, Japan
2Department of Radiation Oncology, Yamagata University Hospital, Yamagata, Japan
3Department of Surgery, Yamagata University Hospital, Yamagata, Japan
1526-8209/$ - see frontmatter ª 2015 The Authors. Published by Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.clbc.2014.09.011performed when the tumor is deemed unresectable.3,4 The primary
drugs used for induction chemotherapy are as follows: anthracyclineSubmitted: Aug 6, 2014; Revised: Sep 27, 2014; Accepted: Sep 30, 2014; Epub:
Nov 15, 2014
Address for correspondence: Takuma Nomiya, MD, PhD, National Institute of
Radiological Sciences, Research Center Hospital for Charged Particle Therapy,
4-9-1, Anagawa, Inage-ku, Chiba 263-8555, Japan
Fax: þ81-43-206-6506; e-mail contact: t_nomiya@nirs.go.jp
Clinical Breast Cancer April 2015 - 161
Ta
bl
e
1
Pa
tie
nt
Ch
ar
ac
te
ris
tic
s
Pa
tie
nt
Ag
e,
Ye
ar
s
Se
x
TN
M
St
ag
e
Pr
im
ar
y
Le
si
on
Hi
st
ol
og
y
Hi
st
or
y
of
Ch
em
ot
he
ra
py
Tu
m
or
Di
am
et
er
(M
ax
im
um
)
M
et
as
ta
si
s
Sy
m
pt
om
s
1
62
F
T4
bN
2M
0
IIIb
Ri
gh
t
br
ea
st
ID
C
(s
ol
id
-t
ub
ul
ar
)
W
ee
kl
y
PT
X
x4
(c
ou
rs
es
),
FE
C
x5
,
3
W
ee
kl
y
DO
C
x3
(P
D)
15
.5
cm
Ax
LN
Sk
in
ul
ce
r,
pa
in
,
bl
ee
di
ng
2
48
F
T4
bN
3M
1
IV
Le
ft
br
ea
st
ID
C
(s
ol
id
-t
ub
ul
ar
)
FE
C
x3
,
DO
C
x3
,
TS
-1
da
ily
(P
D)
16
cm
Ax
LN
,
lu
ng
,
liv
er
Sk
in
ul
ce
r,
pa
in
,
ed
em
a
3
58
F
T4
bN
1M
1
IV
Le
ft
br
ea
st
ID
C
(s
ci
rrh
ou
s)
FE
C
x2
,
W
ee
kl
y
PT
X
w
ith
HE
R
x4
,
VN
B
w
ith
HE
R
x1
(P
D)
22
cm
Sc
LN
Sk
in
ul
ce
r,
pa
in
,
ed
em
a,
bl
ee
di
ng
Ab
br
ev
ia
tio
ns
:
Ax
LN
¼
ip
si
la
te
ra
la
xil
la
ry
lym
ph
no
de
(s
);
DO
C
¼
do
ce
ta
xe
l;
F
¼
fe
m
al
e;
FE
C
¼
5-
ﬂ
uo
ro
ur
ac
il,
ep
iru
bi
ci
n,
an
d
cy
cl
op
ho
sp
ha
m
id
e;
HE
R
¼
He
rc
ep
tin
(tr
as
tu
zu
m
ab
);
ID
C
¼
in
va
si
ve
du
ct
al
ca
rc
in
om
a;
PT
X
¼
pa
cl
ita
xe
l;
Sc
LN
¼
su
pr
ac
la
vic
ul
ar
lym
ph
no
de
(s
);
TN
M
¼
tu
m
or
,
no
de
,
m
et
as
ta
se
s;
TS
-1
¼
te
ga
fu
r-
gi
m
er
ac
il-
ot
er
ac
il
po
ta
ss
iu
m
;
VN
B
¼
vin
or
el
bi
ne
.
Modiﬁed SIB RT for Locally Advanced Unresectable BC
162 -(doxorubicin), taxanes (paclitaxel and docetaxel), cyclophospha-
mide, 5-ﬂuorouracil, and so on.
In some cases, curative surgery and postoperative RT are per-
formed for good responders to induction chemotherapy; in other
cases, chemotherapy (and/or RT) is performed for nonresponders
to induction chemotherapy.2 However, a standard treatment for
locally advanced breast cancer (eg, large T4 tumor) has yet to be
established. In this study, we used a new irradiation technique for
advanced breast cancer patients, and report the efﬁcacy and feasi-
bility of this new approach.
Patients and Methods
Patients
Our investigation was designed as a prospective study of modiﬁed
simultaneous integrated boost (SIB) RT for far-advanced cancer.
The primary end point was deﬁned as local response (rate of
complete response and partial response); secondary end points
were deﬁned as toxicity, quality of life (QOL), and overall sur-
vival rate. Histologically proven breast cancer patients with large
( 10 cm) and unresectable tumors were enrolled in the study.
Patients were enrolled in the study regardless of the presence or
absence of previous surgery, chemotherapy, and/or hormone
therapy. Patients with untreated advanced breast cancer, recur-
rent breast cancer, and treatment-resistant breast cancer were also
included in the study. However, patients with a past history of
thoracic RT were excluded. Patients aged 20 years or older were
included, as were patients with a performance status of 0 to 4.
Written informed consent was obtained from all enrolled pa-
tients. This study was been approved by the institutional review
board (H22-97).
Radiotherapy
Four- to 10-MV photon and 4- to 20-megaelectron volt (MeV)
electron beams from a high-energy linear accelerator were used for
treatment. Irradiation was performed once a day with 5 fractions
per week. Immobilization devices were used as necessary. Skin
markers and image guidance (using ﬂat panel detector) were used
in the setup process. Irradiation was performed under shallow
breathing without respiratory gating. Computed tomography-
based RT planning was performed using XiO (Elekta Inc,
Tokyo, Japan), and dose distribution was calculated using a su-
perposition algorithm. The macroscopic tumor was deﬁned as
gross target/tumor volume (GTV), and metastatic lesion was also
regarded as GTV. The subclinical region (10 mm) around GTV
and level I to III axillary lymph node (LN) area (and supra-
clavicular LN area if there was LN metastasis) was deﬁned as
clinical target volume (CTV). The target volume, including CTV
and setup margins of 5 to 10 mm, was deﬁned as planning target
volume (PTV).
Modiﬁed SIB Technique
The standard SIB technique involves irradiating CTV with a
prophylactic dose and GTV with a curative dose. For example, RT
with standard SIB is used for head and neck tumors with regional
LN metastasis. The technique enables a prophylactic dose of radi-
ation to be delivered to the LN region with higher doses to the
primary tumor and metastatic lesion.5-7 Because a complex doseClinical Breast Cancer April 2015
Table 2 Details of the Radiotherapy
Patient RT Number Target Modality
Voltage
(MV/MeV) Fields, n Total Dose
Dose per
Fraction Frs
Treatment
Schedule (Days
From the Start)
Total Dose (Part
of the Tumor)
Total Dose
(Normal Tissue)
1 1 BR and LN (part) E 12 1 20 Gy 4 Gy 5 1-7
2 BR and LN X 4 2 30 Gy 2 Gy 15 8-28
3 BR and LN X 4 2 20 Gy 2 Gy 10 29-43
3’ BR and LN (part) E 6 1 20 Gy 2 Gy 10 29-43
4 BR and LN X 4 and 10 2 20 Gy 2 Gy 10 44-58
110 Gy 70 Gy
2 1 BR (part) E 12 1 20 Gy 4 Gy 5 1-7
1’ LN (part) E 16 1 20 Gy 4 Gy 5 1-7
2 BR and LN X 4 2 50 Gy 2 Gy 25 14-52
2’ BR (part) E 12 1 50 Gy 2 Gy 25 14-52
2’’ LN (part) E 16 1 50 Gy 2 Gy 25 14-52
3 BR and LN X 4 2 10 Gy 2 Gy 5 55-59
3’ Left BR (part) E 6 1 10 Gy 2 Gy 5 55-59
3’’ LN (part) E 9 1 10 Gy 2 Gy 5 55-59
140 Gy 60 Gy
3 1 BR X 10 2 28 Gy 2 Gy 14 1-21
1’ BR (part) X 10 2 30.8 Gy 2.2 Gy 14 1-21
2 BR X 10 2 14 Gy 2 Gy 7 22-32
2’ BR (part) X 10 2 14 Gy 2 Gy 7 22-32
3 BR X 4 and 6 3 20 Gy 2 Gy 10 33-45
4 BR X 4 2 10 Gy 2 Gy 5 47-54
5 BR (part) E 6 1 10 Gy 2 Gy 5 56-63
128.8 Gy 72 Gy
The RTs of the same number were performed simultaneously (modiﬁed simultaneous integrated boost technique). “Part” means irradiation to the part of the tumor without irradiation to normal tissues.
Abbreviations: BR ¼ breast tumor; E ¼ electron beam; LN ¼ lymph node metastasis; MeV ¼ mega-electron-volt; RT ¼ radiotherapy; X ¼ x-ray.
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164 -distribution is required, RT with standard SIB usually involves
intensity-modulated RT (IMRT).
In this study, normal tissue tolerance dose limits were strictly
followed; the dose to GTV was increased as much as possible
without exceeding tolerance dose. Upper limits of total dose of
normal thoracic tissues were deﬁned as follows (in 2-Gy per frac-
tion): skin, 60 Gy  30 cm2, 70 Gy  10 cm2, 80 Gy  1 cm2;
ipsilateral lung, 45 Gy  1/3 volume, 70 Gy  1 cm3; heart,
45 Gy  2/3 volume, 60 Gy  1/3 volume; rib, 66 Gy  1/3
volume (for necrosis, not for fracture); spinal cord, 50 Gy  1 cm,
46 Gy  10 cm; and fat/muscle, 80 Gy  1 cm3.8-10
Maximum dose to GTV was not deﬁned, and heterogeneity in
the dose distribution of GTV was allowed. For RT planning in this
study, we used 3-dimensional conformal radiation therapy and
IMRT. An equivalent dose in 2 Gy per fraction (EQD2Gy) was
calculated using the following formula: EQD2Gy ¼ (total dose) 
(dose per fraction þ a/b)/(2 þ a/b).11 If there were no annotations,
a simple cumulative dose was described.
Other Treatments and Evaluations
Chemotherapy, hormone therapy, and molecular targeted treat-
ments during RT were permitted. Anticancer drug regimens were
not restricted. The toxicity of the treatment was evaluated according
to the Common Terminology Criteria of Adverse Events, version
4.0.12 Each symptom of the patients was evaluated from subjectiveFigure 1 Radiotherapy (RT) Planning for Patient 2. (A) Initial Treatm
20 Gy/5 Fractions/1 Week). (B) The Second Treatment (RT
Clinical Target Volume Were Included in the 2-Gy Area, W
2 Gy [ 4 Gy/Fraction Is Irradiated With the Modiﬁed Sim
Treatment (RT No. 3). Although Only RT No. 3 Is Displayed,
Planning With the Modiﬁed SIB Technique. (D) The Appro
Modiﬁed SIB Technique. The Total Dose to the Part of GTV
Normal Tissue Does Not Exceed Tolerance Dose
Clinical Breast Cancer April 2015and objective ﬁndings using a numerical rating scale from 0 (normal
or absence of symptoms) to 10 (worst possible or unbearable pain).
Patients received a physical examination weekly during the RT
treatment period, and received a physical examination monthly after
the completion of RT treatment.
Results
Until March 2012, 3 patients with locally advanced breast
cancer were referred for RT, and all 3 patients were treated using
RT and the modiﬁed SIB technique. Patient characteristics are
shown in Table 1. The 3 patients were diagnosed with adenocar-
cinoma (invasive ductal carcinoma). Chemotherapy regimens, FEC
(5-ﬂuorouracil, epirubicin, and cyclophosphamide), taxanes (pacli-
taxel or docetaxel), and/or Herceptin (trastuzumab) were initiated
for all 3 patients because there was no indication for surgery.
However, all 3 patients were eventually categorized with progressive
disease, and were therefore introduced to the department of radia-
tion oncology. All patients had extremely large tumors of > 15 cm
with symptoms of cancer pain, skin ulcer, oozing, edema, and so on.
The patients’ schedules and RT parameters are shown in Table 2.
Day 1 in Table 2 is deﬁned as the ﬁrst day of RT, and RT described
with the same number indicates the same schedule. For example,
RT 3 and 3’ of patient 1 were performed on the same schedule;
therefore, 4 Gy per fraction per day was given to part of the breast
tumor and metastatic tumors in this series of treatments.ent for Axillary Lymph Node Metastasis (RT No. 1’, E-16 MeV,
No. 2 and No. 2’’). Gross Target/Tumor Volume (GTV) and
ith Additional Irradiation of 2 Gy to the Part of GTV (2 Gy D
ultaneous Integrated Boost [SIB] Technique). (C) The Third
There Were Additional Fields (RT No. 3’ and No. 3’’) Using Manual
ximate Dose Distribution Derived From the RT Plans Using the
Reaches 140 Gy (Simple Cumulative Dose), but the Total Dose to
Figure 2 Macroscopic Findings for Patients 1, 2, and 3. (A) Patient 1 Before Radiotherapy (RT). (D) Patient 1 After RT (Day 80).
The Skin Defect Was Shrinking at That Time. (B) Patient 2 Before RT. (E) Patient 2 After RT (Day 142). The Skin Defect
Has Almost Disappeared. (C) Patient 3 Before RT. (F) Patient 3 After RT (Day 90). Although a Large Skin Defect Remained,
Regeneration of the Surrounding Normal Tissue Has Been Observed
Takuma Nomiya et alThe RT plans for patient 2 are shown in Figure 1. Figure 1A
shows the RT for metastatic LNs (this RT and another RT for the
breast tumor do not overlap). Figure 1B shows the RT for metastatic
LNs using the modiﬁed SIB technique (sum of RT 2 and 2’’).
Figure 1C shows RT 3 of patient 2 (RT 3’ and 3’’ were manually
planned and combined). Figure 1D shows the approximate dose
distribution for the sum of all RT plans for patient 2. Although the
total dose (cumulative dose) to the part of the tumor exceeds 140
Gy, the total dose to the normal tissues (axilla or chest wall) was
60 to 70 Gy. Assuming a/b of the tumor was 10, a 2-Gy equiv-
alent dose to the part of GTV was calculated as 163 Gy, whereas
the dose to the normal tissues was almost the same (60-70 Gy).
Regarding the other 2 patients, total doses to the part of the tumor
and the normal tissue were 110 Gy and 70 Gy in patient 1 and
128.8 Gy and 72 Gy in patient 3. The EQD2Gy to the part
of GTV in patient 1 and patient 3 were calculated as 120 Gy and
143 Gy, respectively.
Radiotherapy for these patients was accomplished within 58 to
63 days. There was no treatment delay due to toxicity. Scheduled
treatments were fulﬁlled for all of the patients. Figure 2 shows the
photos of the 3 patients before RT (Figure 2A-C) and after RT
(Figure 2D-F). Figure 2D, E, and F show day 80 of patient 1, Day
142 of patient 2, and Day 90 of patient 3, respectively. The median
time to tumor disappearance was 90 days from the start of RT.
Although much time was required, irradiated tumors disappeared
macroscopically in all patients.
Local cancer pain was relieved in all patients. Considering skin
ulceration in all 3 patients, the skin defect area was reduced inpatient 1 and skin defect caused by tumor almost disappeared in
patient 2. The largest skin defect caused by tumor in patient 3 was
greatly reduced, but did not disappear (Figure 2D-F). Arm edema in
2 patients improved with a reduction in tumor volume. Tumor
odor also diminished with a reduction in tumor volume. The main
toxicity from RT was radiation dermatitis of Grade  2. Skin defect
after tumor disappearance was not considered to be treatment
toxicity because it was deemed a complication of the tumor. There
were no other deﬁnite toxicities from RT using the modiﬁed SIB
technique. The 3 patients died 5 months, 5 months, and 8 months,
respectively, after the start of RT. All 3 patients developed (or had
developed) distant metastases. Two patients died from metastatic
progression, whereas the third died from uncontrolled bleeding
from the skin defect where the tumor existed. For these 3 patients,
the cause of death was categorized as cancer-related.
The major symptoms of these patients were pain, hemorrhage,
odor, and edema (arm). There were fewer changes in each
symptom in the ﬁrst 2 to 3 weeks from the start of RT. However,
the score of each symptom improved as the treatment progressed.
Pain relief tended to appear early after the start of irradiation,
whereas the improvement of edema tended to appear late after
the start of irradiation. The patients were able to discontinue the
treatment if they felt pain in continuing the treatment, and
the patients conﬁrmed whether or not they wanted to continue
the treatment every week during the treatment. All of the patients
actively wished to continue the scheduled treatment, and there
was no request from any of the patients to discontinue the
treatment.Clinical Breast Cancer April 2015 - 165
Figure 3 (A) The Concept of Standard Simultaneous Integrated
Boost (SIB) Radiotherapy. The Whole Clinical Target
Volume (CTV) Is Irradiated With a Prophylactic Dose,
Whereas Gross Target/Tumor Volume (GTV) Is
Irradiated With a Higher Curative Dose. Generally,
Dose Distribution in GTV Is Uniform. (B) The Concept
of Modiﬁed SIB Radiotherapy in the Present Study.
The Whole CTV Is Irradiated With a Prophylactic
Dose. Further, a Part of GTV Is Irradiated With an
Extremely High Dose Using Additional Field. However,
Irradiation to the Normal Tissue Does Not Exceed the
Tolerance Dose. Because Normal Tissue Does Not
Exist Outside GTV (Normal Tissue Has Already Been
Lost to the Tumor), Radiation Injury Will Not Occur
Even If Irradiated by > 100 Gy
Modiﬁed SIB RT for Locally Advanced Unresectable BC
166 -Discussion
Because the required dose to control the tumor increases as the
size of the tumor increases,13-15 the control probability of adeno-
carcinoma of more than 10 cm is extremely low with a normal tissue
tolerance dose.
In this study, using a new RT technique the giant tumor was
irradiated with > 100 Gy without exceeding the tolerance dose to
the normal tissue. A conventional concept of RT recommends a
homogeneous dose distribution in PTV. Contrary to conventional
concept, an SIB method that can alter dose intensity according to
site has recently been reported.5-7 This technique enables irradiation
at a prophylactic dose to CTV and a higher (curative) dose to GTV,
simultaneously. However, dose distribution to GTV is uniform in
this standard SIB technique (Figure 3A).
Compared with standard SIB methodology, the modiﬁed SIB
technique in this study delivered an extremely high dose to the part
of GTV without exceeding the normal tissue tolerance dose
(Figure 3B). Because of the priority that irradiation to normal tissue
does not exceed tolerance levels, dose distribution to GTV is notClinical Breast Cancer April 2015always uniform. This is the pivotal difference between the general
and the modiﬁed SIB techniques in the current study. The control
probability of the extremely high-dose area in GTV will signiﬁcantly
increase, which is the same as the tumor volume being reduced by
half. Based on the evidence that tumor volume and the required
irradiation dose correlate, volume reduction of the tumor will
increase local control probability. However, because sufﬁcient
CTV/PTV margins would increase the risk of toxicity of the sur-
rounding normal tissues, unnecessary margins should be cut from
the simultaneous boost irradiation ﬁeld to protect such tissue
(Figure 1A and B: electron beam).
Response/Clinical Course
The tumor of patient 2 (Figure 2B) seemed to be radio-resistant,
and almost no response was observed at the end of RT (Day 55).
However, the tumors shrunk remarkably at day 94, and almost
disappeared. Skin defects also almost disappeared at 3 months after
RT (Figure 2E). Adenocarcinoma is radio-resistant compared
with squamous cell carcinoma, and the response to irradiation of
adenocarcinoma tends to be slow. Therefore, tumor response should
be evaluated with sufﬁcient long-term observation.
Quality of Life and Symptoms
Giant tumors cause various symptoms such as cancer pain, skin
ulcer, tumor bleeding, odor, fever, edema, joint range-of-motion
limitation, and so on.16 These symptoms were seen in the 3 pa-
tients in this study. Although cancer pain or tumor bleeding might
be improved without tumor disappearance, other symptoms will
not improve without tumor shrinkage. In our study, these
symptoms abated with tumor disappearance. Skin defects, how-
ever, persisted after tumor disappearance in all patients. In patient
2, the skin defect was large during treatment, but as the tumor
decreased, the defect also decreased (Figure 2E). In contrast to skin
necrosis caused by radiation, the normal skin around the defect
that was replaced by the tumor has the potential to regenerate.
When the tumor (which inhibits regeneration of the skin) disap-
pears, the surrounding normal skin begins to regenerate, even
during RT. This phenomenon has also been observed in other
normal tissue such as esophageal ﬁstula after tumor disappear-
ance.17 These clinical experiences suggest that RT need not be
stopped because of a skin defect. In this study, reduction of skin
defect and regeneration of normal skin were observed in all
patients.
One of the problems is the signiﬁcance of the radical treatment
for the patients with extremely poor prognosis such as the patients
this study. However, all of the patients actively wished to continue
the treatment, and all of the patients were delighted to see the
disappearance of the huge tumor. Regarding QOL, tumor shrinkage
or disappearance using the modiﬁed SIB RT is thought to yield
signiﬁcant merit.
Patient Outcomes
The 3 patients in our study died in 5 to 7.5 months after the start
of RT. It is considered that there are 2 major problems to obtain long
survival in these patients. One is to control the huge locally advanced
tumor, and the other is to control the small but multiple distant
metastases. Long-term survival cannot be obtained without solving
Takuma Nomiya et alboth of the problems. Although long-term survival could not be
obtained, the patients were considered to be 1 step closer to complete
cure with control of the local tumor with modiﬁed SIB RT.
Conclusion
Radiotherapy using the modiﬁed SIB technique for far-advanced
breast cancer patients was analyzed. Although a great deal of care
was required in delivering extremely high doses to the tumor, this
technique enabled control of extremely large tumors that could not
be controlled with conventional RT. In future, an increase in the
number of patients included in the study and establishment of the
technique will be required.
Limitations
Although it has been more than 3 years from the start of this trial,
the number of enrolled patients was 3. The number of patients with
unresectable T4 breast tumor is very small, and the patients who
undergo RT in that group is even less. Although the number of
breast cancer patients in this trial was very small, we analyzed the
patients using the limited number because the expected effect was
obtained in all 3 cases.
Clinical Practice Points
 Generally, patients with unresectable T4 tumor have had to
chose only chemotherapy or palliative radiotherapy.
 This is the ﬁrst paper that demonstrated controlled huge breast
tumor by radiotherapy of>100 Gy with modiﬁed SIB technique.
 This new technique would demonstrate a possibility of curative
treatment for patients with unresectable tumor who had no
choice but to undergo palliative care.
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